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Abstract
Background: People living in rural Australia are more likely to die in hospital following an acute
myocardial infarction than those living in major cities. While several factors, including time taken to access
hospital care, contribute to this risk, it is also partially attributable to the lower uptake of evidence-based
guidelines for the administration of thrombolytic drugs in rural emergency departments where up to one-
third of eligible patients do not receive this life-saving intervention. Clinical pathways have the potential to
link evidence to practice by integrating guidelines into local systems, but their impact has been hampered
by variable implementation strategies and sub-optimal research designs. The purpose of this study is to
determine the impact of a five-step clinical pathways implementation process on the timely and efficient
administration of thrombolytic drugs for acute myocardial infarctions managed in rural Australian
emergency departments.
Methods/Design: The design is a two-arm, cluster-randomised trial with rural hospital emergency
departments that treat and do not routinely transfer acute myocardial infarction patients. Six rural
hospitals in the state of Victoria will participate, with three in the intervention group and three in the
control group. Intervention hospitals will participate in a five-step clinical pathway implementation process:
engagement of clinicians, pathway development according to local resources and systems, reminders,
education, and audit and feedback. Hospitals in the control group will each receive a hard copy of
Australian national guidelines for chest pain and acute myocardial infarction management. Each group will
include 90 cases to give a power of 80% at 5% significance level for the two primary outcome measures:
proportion of those eligible for thrombolysis receiving the drug and time to delivery of thrombolytic drug.
Discussion: Improved compliance with thrombolytic guidelines via clinical pathways will increase acute
myocardial infarction survival rates in rural hospitals and thereby help to reduce rural-urban mortality
inequalities. Such knowledge translation has the potential to be adapted for a range of clinical problems in
a wide array of settings.
Trial registration: Australia New Zealand Clinical Trials Registry code ACTRN12608000209392.
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Coronary heart disease is a major health problem in Aus-
tralia with a reported 637,900 people diagnosed in 2004–
05[1]. Acute myocardial infarction (AMI), a manifestation
of coronary heart disease, is the leading cause of sudden
death in the Australian population accounting for one in
ten deaths[1,2]
Timely and efficient delivery of thrombolytic drugs to
individuals suffering an acute myocardial infarction sig-
nificantly improves mortality and morbidity and is a
major aim of early treatment when invasive coronary
reperfusion services are not readily available[3,4]. The
National Heart Foundation of Australia (NHFA) and the
Cardiac Society of Australia and New Zealand (CSANZ)
jointly produced clinical guidelines for the management
of AMI, including the administration of thrombolytic
drugs when percutaneous coronary intervention services
are unavailable. These guidelines provide precise recom-
mendations directing which patients should receive a
thrombolytic drug based on presenting symptoms, elec-
trocardiographic (ECG) findings and contraindica-
tions[5].
People living in rural Australia are more likely to die in
hospital following an AMI than people in major cities[6].
Whilst there are obvious problems associated with dis-
tances people travel to access treatment, there also appears
to be lower uptake of national guidelines for thrombolytic
drugs in rural areas, where up to one-third of eligible
patients do not receive this life-saving intervention[7].
Peak Australian bodies, including the NHFA, the Austral-
asian College of Emergency Medicine (ACEM) and the
Cardiac Society of Australia and New Zealand (CSANZ)
have promoted the development of local systems to
improve to uptake of national guidelines [8].
Clinical pathways are structured, locally developed multi-
disciplinary care plans for specific clinical problems that
take into account local resources and make explicit the
local system for clinicians. They are an important tool for
linking evidence to practice and can enhance adherence to
guidelines[9]. However, sub-optimal implementation
processes and study design have compromised the quality
of current evidence regarding the impact of clinical path-
ways on practice[10].
Active, multifaceted approaches have been shown to
improve adherence to guidelines in clinical settings over
passive dissemination strategies. Active approaches
include a combination of audit and feedback, reminder
systems, engaging clinicians and targeted educa-
tion[11,12].
The aim of this cluster randomised controlled trial is to
measure the impact of a multifaceted process of clinical
pathways implementation on thrombolytic delivery for
AMIs managed in rural emergency departments in Aus-
tralia.
Methods
The "Acute myocardial infarction: investigating evidence-
based practice to address the rural disadvantage" study is
being coordinated by the Monash University School of
Rural Health with rural hospitals in the state of Victoria.
In this setting, all hospitals outside of major cities are cat-
egorised as rural [1]. The study is funded by a Faculty Stra-
tegic Grant from the Faculty of Medicine, Nursing and
Health Sciences at Monash University and was registered
with the Australia New Zealand Clinical Trials Registry
(code: 12608000209392) in April 2008.
Ethics approval has been obtained from the Monash Uni-
versity Standing Committee on Ethics involving Humans
and relevant hospital human research ethics committees.
Individual informed consent is not feasible within this
research design and the decision to undertake the research
is the responsibility of participating institutions.
Aim
To determine if a five-step implementation process of
clinical pathways for AMI improves the proportion of
patients receiving a thrombolytic drug and reduces the
average time from presentation at hospital to thrombo-
lytic administration in rural emergency departments.
Objectives
1. To assess performance of rural hospitals against
NHFA recommendations for administration of throm-
bolytic drugs for AMI; and
2. To measure the effect of a five step intervention for
the implementation of clinical pathways in rural hos-
pitals for AMI on:
a) the proportion of eligible patients receiving a
thrombolytic drug, and
b) the time from presentation at hospital to
administration of a thrombolytic drug.
Study Design
A randomised controlled trial will be conducted involving
six rural hospitals that treat and do not routinely transfer
AMI patients. As displayed in table 1, pairs of hospitals
were matched according to the anticipated number of eli-
gible patients and on the basis of geographical separation
in order to minimise the risk of a control hospital being
influenced by procedures at an intervention hospital. Ran-Page 2 of 4
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or control (n = 3) groups occurred by a simple coin toss.
Sample size
A 20 minute reduction in time to thrombolytic adminis-
tration represents a modest improvement[7]. A total post
intervention sample size of 90 patients is required to
detect a 20 minute reduction in thrombolytic delivery
time and a 10% improvement in eligible patients receiv-
ing thrombolysis (significance level of 5%, power of 0.8,
and intra-cluster correlation coefficient of 0.283)[13].
Based on anticipated total attendance rates (i.e. 125 eligi-
ble case per annum in each condition) there will be nine
months of pre and nine months of post intervention data
collected.
Intervention
The three intervention hospitals will participate in the five
step implementation process described below. The con-
trol hospitals will receive a hard copy of the relevant
NHFA guidelines. The evidence-based five step interven-
tion within emergency departments to implement clinical
pathways will be a combination of processes proposed by
Doherty & Jones[14] and Kinsman et al.[7]. In brief, the
three month implementation process entails:
1. Engaging clinicians
The Chief Investigator will hold group discussions with
emergency department medical and nursing staff regard-
ing barriers and facilitators for clinical pathways whilst
local clinicians will be recruited as Research Assistants. It
is hoped that the employment of local clinicians will facil-
itate local opinion leadership.
2. Clinical pathway development
Hospital-specific clinical pathways will be developed by
Research Assistants in collaboration with clinicians at
each emergency department. Pathway content will be con-
sistent with NHFA and CSANZ guidelines for chest pain
and AMI management, and will incorporate local
resources and systems.
3. Reminders
Reminder visits by the Chief Investigator will occur twice
following implementation to liaise with clinical staff.
Research Assistants will be tasked with reminding medical
and nursing staff about the clinical pathway to promote
utilisation.
4. Education
The Research Assistant and Chief Investigator will facili-
tate education sessions during implementation to review
evidence underpinning the clinical pathway and reinforce
the role of the pathway itself. All staff will receive written
material regarding thrombolytic drugs, including summa-
ries of the national guidelines.
5. Audit and feedback
Audit results reflecting compliance with the clinical path-
way and thrombolysis administration will be communi-
cated by the Chief Investigator to emergency department
staff twice during the implementation of the clinical path-
way. Participants will be encouraged to express their views
on the advantages and pit-falls of the clinical pathway.
Data Collection
Medical records will be identified by an International
Classification of Diseases (ICD 10) report and audited
using a specifically-designed data protocol. Initial data
will include type of infarct, gender and age. Information
regarding whether criteria were met for a thrombolytic
drug will be checked. If criteria were met, then whether a
thrombolytic was administered will be recorded, as will
the time in minutes from presentation to administration.
The level of adoption of the clinical pathway will be meas-
ured by identifying the presence of the pathway in audited
records and by degree of documented completion of the
pathway. A co-investigator will review 10% of the medical
records to confirm accuracy of data extraction.
Data Analysis
Use of thrombolytic drugs will be categorised as yes/no
for each eligible patient, and intervention and control
Table 1: Geographic characteristics and anticipated number of patients per site.
Kilometres between matched hospitalsa Mean number of eligible patients per yearb
Intervention
Control
318 60
55
Intervention
Control
463 50
50
Intervention
Control
155 15
20
a Source: Google Earth
b Estimates based on previous research [7]Page 3 of 4
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hospital groups will be compared at baseline and follow-
up using a standard Chi-squared test. An independent
sample t-test will be used to compare time to thrombo-
lytic delivery between intervention and control groups at
baseline and follow-up. Matched t-tests will assess differ-
ences between baseline and follow-up for both the inter-
vention and control groups. Between-group comparisons
allowing for the clustering of data will be undertaken.
Documented usage of the clinical pathway will be meas-
ured by simple descriptive statistics such as percentage of
AMI cases in which the pathway was used and proportion
of the chart completed.
Discussion
The evidence for clinical pathways remains inconclusive
and the reasons for the variable results reported may relate
to both implementation strategies and research designs. It
is important to determine rigorously whether clinical
pathways have an integral role to play in enhancing com-
pliance with evidence-based practice. Randomisation of
individual patients within a single ward or hospital to
complex interventions such as clinical pathways will lead
to contamination of comparable samples and a high risk
of bias. In these situations a cluster randomised control-
led trial is a preferred method to minimise the influence
an intervention may have on clinical practice in control
groups.
This study will contribute to the knowledge base on what
is required to translate evidence into practice in rural set-
tings. In this study improved compliance with thrombo-
lytic guidelines via clinical pathways will increase AMI
survival rates in rural hospitals and help reduce rural-
urban mortality inequalities. Such translation science will
have the potential to be applied in a range of clinical set-
tings for many different conditions.
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